1、该刊只有国际刊号。

2、投稿方式：在线投稿。

3、官网网址：

https://onlinelibrary.wiley.com/journal/23987324

4、投稿系统：https://mc.manuscriptcentral.com/pro6

5、主办单位网址：

http://www.sd-cancer.com/news_hos/2018/APdRBwdG.html

（山东省肿瘤防治研究院）

相关网址：http://www.cjcpt.cn/

（中华肿瘤防治杂志社；可从此网页进入Precision Radiation Oncology期刊官网）

6、官网邮箱：cjcptmj@126.com

yuanshuanghu@sina.com（编辑部主任袁双虎教授）

7、官网电话：0531-67626704

8、期刊刊期：季刊，逢季末月出版。

9、微信公众号：山东省肿瘤医院；

中华肿瘤防治杂志（cjcpt2015）

10、投稿作者免收审稿费和发表费。

（官网信息；微信公众号“cjcpt2015”信息）

2021年10月15日星期五

《精准放射肿瘤学（英文）》期刊简介

（Precision Radiation Oncology）

【微信公众号“cjcpt2015”信息】

Precision Radiation Oncology（PRO）是一本关于精准放射肿瘤学的国际性英文期刊，目前已被Scopus、DOAJ 和Embase 3大数据库全文收录。

PRO由山东省肿瘤防治研究院主办，中国工程院于金明院士和美国俄克拉荷马大学医学院李敏教授共同担任主编，袁双虎教授担任编辑部主任，国内外知名专家担任编委并参与同行评议，受中美放射肿瘤协作学会和中国抗癌协会学术支持。PRO以“追踪国际肿瘤放射医学研究动向，搭建肿瘤放射医学研究互动平台，报道放射医学研究最新学术成果，弘扬放射医学精准诊断治疗理念”为办刊宗旨，刊文涵盖肿瘤基础实验研究、流行病学、影像诊断、放射治疗、介入与核医学等临床与基础医学研究领域。

栏目包括：editorial, original article, clinical guideline, consensus, review, case report, letters to the editor.

期刊关键词：oncology, radiation, clinical medicine, basic medicine, precision medicine, radiotherapy, radiophysics, intervention, diagnostic imaging, nuclear medicine.

PRO为OA模式，所有文章均可免费下载阅读。文章一经发表，可以第一时间被全球读者检索、阅读和下载。

为了促进学术交流，投稿作者免收审稿费和发表费。欢迎广大临床医务工作者、科研工作者、肿瘤放射医学相关领域的专家学者踊跃投稿。

承蒙鼎助，不胜感谢!

电话：0531-67626604/67626704

邮箱：cjcptyjm@126.com

投稿网址：www.precisionradiationoncologyjournal.com

Precision Radiation Oncology 杂志社

2020-12-07

《精准放射肿瘤学（英文）》作者指南

（Precision Radiation Oncology）

【官网信息】

Author Guidelines

Please note that Precision Radiation Oncology is a fully open access journal. All articles accepted for publication will be published open access under a creative commons license, making them immediately freely available to read, download and share. The Article Publication Charge is currently waived for all manuscripts submitted to the journal. For more information on the Wiley Open Access publishing program visit the Wiley Open Access page.

1. MANUSCRIPT SUBMISSION

Thank you for your interest in Precision Radiation Oncology. Please read the complete Author Guidelines carefully prior to submission. Note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium. Once you have prepared your submission in accordance with the Guidelines, manuscripts should be submitted online at https://mc.manuscriptcentral.com/pro6. We are looking forward to your submission.

The submission system will encourage authors to use an ORCID iD (a unique author identifier) to help distinguish their work from that of other researchers. Click here to find out more.

2. EDITORIAL CONSIDERATIONS

Aims and Scope

Precision Radiation Oncology aims to offer a forum for collaboration and exchange of comprehensive and cutting-edge information on basic, translational, and clinical research in radiation oncology. The editors encourage contributions relevant to radio diagnosis, radiotherapy, radiation physics, radiation biology, interventional therapy, and nuclear medicine in cancer, including basic cancer research, as well as translational and clinical cancer research.

The editors welcome submissions in the form of Original Articles, Clinical Guidelines, Consensus, Commentaries, Editorials, Reviews, Meeting Reports, Case Reports, Brief Reports, Research Letters, Letters to the Editor, and Perspective.

Precision Radiation Oncology is supported by the Sino-American Network for Therapeutic Radiology and Oncology and the Chinese Anti-Cancer Association.

Review Process

The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are single-blind peer reviewed. Papers will only be sent to review if the Editor-in-Chief determines that the paper meets the appropriate quality and relevance requirements.

In-house submissions, i.e. papers authored by Editors or Editorial Board members of Precision Radiation Oncology, will be sent to Editors unaffiliated with the author or institution and monitored carefully to ensure there is no peer review bias.

Wiley's policy on confidentiality of the review process is available here.

Manuscripts are assigned sequentially to Associate Editors. An Associate Editor solicits reviewers (typically, two external reviews are sought). The reviewers’ evaluations and Associate Editor’s comments are compiled by the Editor-in-Chief for disposition and transmittal to the authors.

The Editor-in-Chief will advise authors whether a manuscript is accepted, should be revised or is rejected. Minor revisions are expected to be returned within four weeks of decision; major revisions within three months. Manuscripts not revised within these time periods are subject to withdrawal from consideration for publication unless the authors can provide extenuating circumstances.

A number of manuscripts will have to be rejected on the grounds of priority and available space. A manuscript may be returned to the authors without outside review if the Editor-in-Chief and Associate Editor find it inappropriate for publication in the Journal. Similarly, the Editors may expedite the review process for manuscripts felt to be of high priority in order to reach a rapid decision. Such ‘fast-track decisions’ will normally occur within one week of receipt of the manuscript.

The Editor-in-Chief’s decision is final. If, however, authors dispute a decision and can document good reasons why a manuscript should be reconsidered, a rebuttal process exists. In the first place, authors should write to the Editor-in-Chief.

Suggest a reviewer

Authors may provide the Editor-in-Chief with the names, addresses and email addresses of up to three suitably qualified individuals of international standing who would be competent to referee the work, although the Editor-in-Chief will not be bound by any such nomination. Authors may advise of any individual who for any reason, such as potential conflict of interest, might be inappropriate to act as a referee, again without binding the Editor-in-Chief. This information will be requested via the submission system.

3. ETHICAL CONSIDERATIONS

Authorship

The author submitting a manuscript must ensure that all authors listed are eligible for authorship. Each author should take responsibility for substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work AND drafting the work or revising it critically for important intellectual content AND final approval of the version to be published AND agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. For further information on authorship refer to the ICMJE guidelines: http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html

Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section (for example, to recognize contributions from people who provided technical help, collation of data, writing assistance, acquisition of funding, or a department chairperson who provided general support). Additional information such as ‘X and Y should be considered joint first author’ or ‘X and Y should be considered joint senior author’ may be added as a footnote to the Author Listing/in the Acknowledgements.

Group collaborations: If your research was conducted by a very large collaborative group please list all names and these will be published in an appendix to the article.

Conflict of Interest

The journal requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to, patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company. The existence of a conflict of interest does not preclude publication. If the authors have no conflict of interest to declare, they must also state this in their submission. It is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships. In addition, any financial interests should also be detailed in the journal’s Financial Disclosure form, which will be provided to the corresponding author upon acceptance. The Corresponding Author is responsible for distributing the form to each co-author and returning it to the publisher.

Human Studies and Subjects

For manuscripts reporting medical studies involving human participants, we require a statement identifying the ethics committee that approved the study, and that the study conforms to recognized standards, for example: Declaration of Helsinki; US Federal Policy for the Protection of Human Subjects; or European Medicines Agency Guidelines for Good Clinical Practice.

Images and information from individual participants will only be published where the authors have obtained the individual's free prior informed consent. Authors do not need to provide a copy of the consent form to the publisher; however, in signing the author license to publish, authors are required to confirm that consent has been obtained. Wiley has a standard patient consent form available for use.

Animal Studies

A statement indicating that the protocol and procedures employed were ethically reviewed and approved, and the name of the body giving approval, must be included in the Methods section of the manuscript. We encourage authors to adhere to animal research reporting standards, for example the ARRIVE reporting guidelines for reporting study design and statistical analysis; experimental procedures; experimental animals and housing and husbandry. Authors should also state whether experiments were performed in accordance with relevant institutional and national guidelines and regulations for the care and use of laboratory animals:

• US authors should cite compliance with the US National Research Council's Guide for the Care and Use of Laboratory Animals, the US Public Health Service's Policy on Humane Care and Use of Laboratory Animals, and Guide for the Care and Use of Laboratory Animals.

• UK authors should conform to UK legislation under the Animals (Scientific Procedures) Act 1986 Amendment Regulations (SI 2012/3039).

• European authors outside the UK should conform to Directive 2010/63/EU.

Clinical Trials Registration

We require that clinical trials are prospectively registered in a publicly accessible database and clinical trial registration numbers should be included in all papers that report their results. Please include the name of the trial register and your clinical trial registration number at the end of your abstract. If your trial is not registered, or was registered retrospectively, please explain the reasons for this.

Research Reporting Guidelines

Reporting of randomized controlled trials should follow the guidelines of The CONSORT Statement.

Publication Ethics

This journal is a member of the Committee on Publication Ethics (COPE). Wiley’s Ethics guidelines can also be found at http://exchanges.wiley.com/ethicsguidelines.

Plagiarism Detection

The journal employs a plagiarism detection system. By submitting your manuscript to this journal you accept that your manuscript may be screened for plagiarism against previously published works.

4. MANUSCRIPT CATEGORIES

(1) Original Articles

Word limit: 4000 words maximum including abstract but excluding references, tables and figures. Abstract: 250 words maximum, with sub-headers. References: no limit. Figures/tables: no limit, but 8 figures should be sufficient. Description: Full-length reports of current research in either basic or clinical science.

……

更多详情：

https://onlinelibrary.wiley.com/page/journal/23987324/homepage/forauthors.html